Neosoma, Inc., an innovative medical technology company focused on helping clinicians treat brain cancer, today announced that its AI solutions are connected to the Nuance Precision Imaging Network

GROTON, Mass.–(BUSINESS WIRE)–Neosoma, Inc., an innovative medical technology company focused on helping physicians treat brain cancer, today announced that its AI solutions are connected to the Nuance Precision Imaging Network™. Neosoma develops an integrated portfolio of advanced software products based on artificial intelligence combined with a clinical management software platform.

Neosoma’s comprehensive software-as-a-service (SaaS) solution is a unique technology in the neuro-oncology field that helps physicians make treatment decisions and create an enhanced patient experience, with the aim of improving and improving clinical outcomes increase clinical process efficiency and cost reduction. The company recently received FDA approval for Neosoma HGG to support clinical teams in neuro-oncology treating patients with high-grade glioma (HGG).

Leveraging the nationwide reach of Nuance PowerScribe and Nuance PowerShare diagnostic imaging solutions, the Nuance Precision Imaging Network connects radiologists, providers, health plans, self-insured employers, life science companies and other imaging stakeholders to expand access to precision diagnostics and therapy. Increasing healthcare efficiency and reducing costs. The secure AI-powered cloud platform enables the seamless sharing of AI insights from diagnostic imaging to improve clinical decision-making, enhance care team collaboration, and facilitate earlier disease detection and treatment for better patient outcomes.

“The collaboration between Nuance and Neosoma will help accelerate the adoption and implementation of these important technologies in clinical practice while maintaining a high level of data security and privacy. The connection to Nuance’s Precision Imaging Network offers our clinical customers a seamless method to rapidly implement Neosoma’s novel solutions through a trusted partner. We are very excited about our relationship with Nuance and what it means to the future of neuro-oncology,” said Ken Kolodziej, CEO and co-founder of Neosoma.

For more information, visit: www.neosomainc.com

About Neosoma, Inc.

Neosoma is focused on advancing the treatment of brain tumors through an integrated portfolio of innovative artificial intelligence-based software products combined with a clinical management software platform. Neosoma’s comprehensive SaaS solution is the first of its kind in neuro-oncology, helping physicians make better treatment decisions to improve clinical outcomes.

Beginning with its first software-based medical device, the Neosoma HGG, the company is developing a full suite of software technologies to become the global leader in neuro-oncology software.

source

Leave a Reply

Your email address will not be published. Required fields are marked *